A Decade of Experience With Alemtuzumab Therapy for Severe or Glucocorticoid-Resistant Kidney Transplant Rejection

A Decade of Experience With Alemtuzumab Therapy for Severe or Glucocorticoid-Resistant Kidney Transplant Rejection

Alemtuzumab is used as lymphocyte-depleting therapy for severe or glucocorticoid-resistant kidney transplant rejection. However, the long-term efficacy and toxicity of alemtuzumab therapy are unclear. Therefore, all cases of alemtuzumab anti-rejection therapy between 2012 and 2022 in our institution...

Full description

Bibliographic Details
Main Authors: Lukas K. van Vugt, Marieke van der Zwan, Marian C. Clahsen-van Groningen, Madelon van Agteren, Daphne M. Hullegie-Peelen, Brenda C. M. De Winter, Marlies E. J. Reinders, Pedro Miranda Afonso, Dennis A. Hesselink
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-11-01
Series:Transplant International
Subjects:
adverse effects
alemtuzumab
kidney transplant rejection
efficacy
kidney transplantation
Online Access:https://www.frontierspartnerships.org/articles/10.3389/ti.2023.11834/full

Internet

https://www.frontierspartnerships.org/articles/10.3389/ti.2023.11834/full

Similar Items